Carmat develops artificial heart devices designed to replace the function of a failing heart in patients with end-stage heart failure.
Carmat is a French biomedical company that designs, manufactures, and markets artificial heart devices. The company's flagship product is a total artificial heart that uses biological materials and advanced technology to mimic the function of a human heart. Carmat's artificial heart is designed for patients with end-stage biventricular heart failure who are not eligible for heart transplantation. The device has received CE marking in Europe and is undergoing clinical trials. The company went public on Euronext Paris and represents a significant advancement in cardiac medical devices.
Carmat has received investment from 1 venture capital firm.
Carmat develops artificial heart devices designed to replace the function of a failing heart in patients with end-stage heart failure.
Carmat has received investment from Kurma Partners. These venture capital firms and investors provide both capital and strategic support.
Carmat has raised €63M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Carmat was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
Carmat operates in the Biotech sector. Carmat develops artificial heart devices designed to replace the function of a failing heart in patients with end-stage heart failure.
